title: Complications of extracorporeal life support systems using heparin-bound surfaces. The risk of intracardiac clot formation.
abstract: Extracorporeal life support with heparin-coated extracorporeal membrane oxygenation circuits are being used with increased frequency in patients who have cardiogenic shock. We report our experience in 30 patients with cardiogenic shock, looking specifically at the complications associated with this form of life support. Thirty patients with a mean age of 46.5 +/- 16.6 years received extracorporeal life support for a mean of 62.8 +/- 41.1 hours (range 0.5 to 159 hours). Twenty-three patients had postcardiotomy cardiogenic shock, five had acute myocardial infarction, and one each had acute cardiac deterioration after a balloon coronary angioplasty and another after pulmonary artery balloon angioplasty. Peripheral (femoral vein to femoral artery) cannulation was used in 24 patients. Limb ischemia developed in 21 patients (70%), renal failure in 17 patients (57%), oxygenator failure requiring change in 13 patients (43%), bleeding requiring reexploration in 12 (40%), and infection in 9 patients (30%). Transesophageal echocardiography revealed intracardiac thrombus formation in 6 patients (20%) and clot was visualized grossly in the pump head in 2 patients (6%) necessitating pump-head change. Nine patients (30%) were discharged home. We conclude that the use of heparin-coated extracorporeal life support without systemic heparinization, especially after protamine has been used to reverse systemic heparinization in patients having postcardiotomy cardiogenic shock, may be dangerous. Extracorporeal life support has introduced new complications unique to itself specifically limb ischemia, oxygenator failure, and pump-head thrombus.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: D D
authors.initials: DD
authors.lastname: Muehrcke
authors.forename: P M
authors.initials: PM
authors.lastname: McCarthy
authors.forename: R W
authors.initials: RW
authors.lastname: Stewart
authors.forename: S
authors.initials: S
authors.lastname: Seshagiri
authors.forename: D A
authors.initials: DA
authors.lastname: Ogella
authors.forename: R C
authors.initials: RC
authors.lastname: Foster
authors.forename: D M
authors.initials: DM
authors.lastname: Cosgrove
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D017548:Echocardiography, Transesophageal; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D005121:Extremities / Q000098:blood supply; D005260:Female; D006331:Heart Diseases / Q000000981:diagnostic imaging / Q000209:etiology*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007511:Ischemia / Q000209:etiology; D008020:Life Support Care; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012770:Shock, Cardiogenic / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000209:etiology*
chemical_list: D006493:Heparin